NeuBio is a Precision NeuroBiology Company

NeuBio utilizes revolutionary technology to discover biological factors involved in Parkinson’s Disease, Alzheimer’s Disease, and Amyotrophic Lateral Sclerosis. NeuBio has discovered and validated, in-silico, 141 novel mRNA biomarkers with the highest precision and reproducibility ever documented in these diseases.

These discoveries lay the foundation for NeuBio’s new precise biological maps that chart human interaction with these conditions.

This revolution in understanding gives rise to an array of new precision diagnostics and therapeutic pathways that will serve all affected by these devastating diseases.

“Much like the successes in oncology, neurology will significantly benefit from the application of sophisticated analysis of molecular sequencing results. NeuBio is on the forefront of this revolution.”

Dr. Alan Wright Chief Medical Officer, bioMerieux & Former Chief Medical & Science Officer, Roche Diagnostics

NeuBio’s Precision Diagnostic Platform

NeuBio’s new biological maps of Alzheimer’s, Parkinson’s, and ALS are revolutionizing diagnostics.

NeuBio is solving very complex problems, with very advanced technology, but at its core is simplicity. The beauty of our method gives clear, human-understandable results that are simple to understand, implement and administer.

NeuBio's diagnostics work by taking a peripheral blood test that is measured using the Next Generation Sequencing (NGS) standard. NGS is highly scalable, mature, and widely understood. No new technology or specialized equipment is needed.

The measurement is taken against the NeuBio “super assay” of clinical algorithms that can diagnose, subtype, and stratify patient conditions.

NeuBio’s diagnostics will be highly accurate, lower cost, and minimally invasive, in stark contrast to the costly, subjective, patient-unfriendly standards available today.

The more our products are used, the ever more precise they become as we ingest more patient data, a virtuous circle with virtue.

Precision Diagnostic Products

Program 2 - Clinical Diagnosis

NeuBio is developing an array of the first-ever blood tests for Parkinson’s, Alzheimer’s, and ALS. These tests will not just confirm diagnosis but also give accurate predictions of disease progression and precise patient stratification.

For example, our Alzheimer’s program can diagnose Alzheimer’s from Mild Cognitive impairment, Alzheimer’s from Asymptomatic Alzheimer’s, Fast Progressors from Slow Progressors, and whether patients with Mild Cognitive Impairment will convert to Alzheimer’s.

NeuBio's first development product is a blood test that discriminates patients between Essential tremor and Parkinsonian tremor, which often leads to misdiagnosis, providing a much cheaper, more accurate, easier to administer alternative to DatScan imaging, which has established clinical utility.

Program 1 - Clinical Trial Screening

There has never been more research activity in Alzheimer’s, Parkinson’s and ALS, there are currently over 1000 active clinical trials.

However, the failure rate in neurology is the highest in all of medicine at over 95%.

With trials costing on average over $200,000 per patient, the financial waste runs into $billions. The human cost of wasted time and hope is immeasurable.

NeuBio’s platform will produce urgently needed precision patient selection screeners that will ensure the right patients are in the right trials, reducing costs, & increasing trial success.

Precision Drug Discovery

Program 1 - New Druggable Targets

24 of NeuBio’s biomarker discoveries have been identified as potential druggable targets. Through industry partnership, NeuBio are investigating candidate development for targets focused on the underlying causality of Alzheimer’s, Parkinson’s, and ALS.

Program 2 - Failed Drug Rescue

Retrospective analysis of clinical trial data can demonstrate if trials would be successful by utilizing NeuBio’s patient screening capabilities. This approach has been employed successfully using our technology for large stakeholders in pharma in other medical fields.